Drug Repurposing Market Size, Share, Competitive Landscape and Trend Analysis Report, by Therapeutic Area : Global Opportunity Analysis and Industry Forecast, 2023-2032

Drug repurposing, also known as drug repositioning is an approach to identify a novel medical indication for a drug. It may involve identification of a novel clinical use for an existing drug approved for a different indication or even finding clinical use for any unapproved drug. It has many advantages over traditional de novo drug discovery approaches, such as significant reduction of the cost and development time for the drug purposing. Drug repurposing is based on polypharmacology, complex diseases such as cancers and neurodegenerative diseases that involve networks of multiple genes, hence require multiple pharmacophores and system biology-based approaches for their therapeutic application. Advances in computation power and field of computational biology, has brought up various opportunitiesto find new treatments for rare diseases using existing compounds. Many academic research groups and startup companies are actively partaking in drug repurposing. Many pharmaceutical companies have formed partnerships with many of these organizations to help facilitate repurposing oftheir existing products. For instance, in 2016,Sanofi S.A. (Sanofi Genzyme) signed a research agreement with Recursion Pharmaceuticals, LLC to identify new uses for Sanofi’s clinical stage molecules formany genetic diseases. Likewise, Astellas Pharma Inc. also has partnered with Biovista Inc., and NuMedii, Inc. for drug repurposing.

The global drug repurposing market experiences growth due to shorter drug development time for repurposed drugs compared to new chemical entities. In addition, advances in the computational power to process large databases has allowed cost-effective solutions to approach drug development. This further drives the growth of the market. However, limited understanding of polypharmaco logical effects of drugs and lack of trained personnel restrains the growth of the market. In contrast, increase in partnership of pharmaceutical companies among various academic research groups and startups to facilitate drug repurposing activities is anticipated to provide lucrative opportunities for the growth of the market.

The drug repurposing market is segmented on the basis of therapeutic area. By therapeutic area, the market is segmented intooncology, CNS disorders, neurodegenerative diseases, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The report provides a comprehensive analysis of the key players of the drug repurposing market including Atomwise, Inc., Biovista, Inc., Centene Corporation (Health Net, LLC)NuMedii, Inc., Recursion Pharmaceuticals, Inc., SOM Innovation Biotech, S.L., Sosei Group Corporation (SoseiHeptares), Exscientia Limited, and Healx. Other players in the clue chain include Pfizer Inc., Johnson & Johnson, Sanofi, Astellas Pharma, GlaxoSmithKline plc, and others.

Key Benefits For Stakeholders

• This report provides a detailed quantitative analysis of the current drug repurposing market trends and futureestimations which assists to identify the prevailing drug repurposing market opportunities. 

• An in-depth market analysis includes various countries, and is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate country-specific plans.

• A comprehensive analysis of the factors that drives and restrains the growth of the global drug repurposing market is provided.

• Region-wise market conditions are comprehensively analyzed in this report.

• An extensive analysis of various countries provides insights that are expected to allow companies to strategically plan their business moves.

• Key market players within the drug repurposing market are profiled in this report and their strategies are analyzed thoroughly, which help to understand the competitive outlook of the market.  

  Drug Repurposing Market Report Highlights

Aspects	Details
By Therapeutic Area	Oncology CNS Disorders Neurodegenerative Diseases Others
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	Centene Corporation (Health Net LLC), Exscientia Limited, Biovista Inc., Healx, NuMedii Inc., Sosei Group Corporation (SoseiHeptares), SOM Innovation Biotech S.L., Atomwise Inc., Recursion Pharmaceuticals Inc.